DARE · Dare Bioscience, Inc.
$1.28
+0.02 (+1.59%)
At close · Jul 24
Market Cap
$19.17M
Shares
14.98M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$1.03M
+10429.4%
FY2025
Net Income
-$13.4M
-230.6%
FY2025
Gross Margin
71.29%
-28.7pp
FY2025
Operating Margin
-1315.51%
+238376.7pp
FY2025
Diluted EPS
-$1.20
-150%
FY2025
Operating Cash Flow
-$9.89M
-280.6%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | $1.03M | $9784 | $2.81M | $10M | $0 | — | — | — | — | $766K | — | $80K | $6000 | $625K | |
| — | $295.8K | $0 | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | $734.39K | $9784 | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | 71.29% | 100% | — | — | — | — | — | — | — | — | — | — | — | — | |
| $3.89M | $5.52M | $14.31M | $21.54M | $30.04M | $30.62M | $20.77M | $8.55M | $6.41M | $984.75K | $72.67K | $25.95M | $11.77M | $9.7M | $15.81M | |
| $9.18M | — | $9.16M | $12.11M | $11.24M | $8.35M | $6.55M | $5.27M | $4.66M | $2.7M | $157.93K | $11.22M | $8.59M | $6.17M | $6.39M | |
| — | $8.76M | $9.16M | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | $1.63M | $42.33K | — | — | — | — | — | — | — | $261K | $192K | $126K | $197K | $346K | |
| $12.59M | $14.29M | $23.46M | $33.75M | $41.39M | $39.07M | $27.4M | $14.34M | $16.88M | $11.18M | $630.59K | $37.17M | $20.36M | $15.87M | $22.2M | |
| -$11.97M | -$13.55M | -$23.45M | -$30.94M | -$31.39M | -$39.07M | -$27.4M | -$14.34M | -$16.88M | -$11.18M | -$630.59K | — | — | — | — | |
| — | -1315.51% | -239692.2% | -1101.89% | -313.85% | — | — | — | — | — | -82.32% | — | — | — | — | |
| — | -$11.92M | -$23.41M | — | — | — | — | — | — | — | -$369.59K | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | $322.63K | $42.1K | $2.43M | $1.08M | $1.49M | $567K | |
| $98K | — | — | — | — | — | — | — | — | — | $86K | $10K | $9000 | $2000 | $2000 | |
| -$356.86K | -$153.06K | $981.49K | $778.49K | $437.75K | $2520 | $1514 | $81.05K | $143.5K | -$322.63K | -$2.15M | -$2.42M | -$3.06M | -$1.28M | -$526K | |
| — | -$13.54M | -$4.05M | -$30.16M | -$30.95M | -$38.7M | -$27.4M | -$14.26M | -$16.81M | -$11.52M | -$673K | — | — | — | — | |
| — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $3200 | $0 | — | — | — | — | — | |
| -$12.02M | -$13.4M | -$4.05M | -$30.16M | -$30.95M | -$38.7M | -$27.4M | -$14.26M | -$16.74M | -$11.5M | -$672.69K | -$39.59M | -$23.34M | -$17.14M | -$22.1M | |
| — | -1300.66% | -41430.9% | -1074.17% | -309.48% | — | — | — | — | — | -87.82% | — | -29177.5% | -285716.67% | -3536.16% | |
| — | -$13.4M | -$4.05M | -$30.16M | -$30.95M | -$38.7M | -$27.41M | -$15.05M | -$16.74M | — | -$39.31M | -$39.59M | -$23.34M | -$17.14M | -$22.17M | |
| -$11.98M | -$13.39M | -$4.12M | -$30.17M | -$31.14M | -$38.76M | -$27.4M | -$15.06M | -$16.82M | -$11.52M | -$672.69K | — | — | — | — | |
| USD/shares | — | -$1.20 | -$0.48 | -$4.15 | -$4.44 | -$7.56 | -$10.92 | — | — | — | — | — | — | — | — |
| USD/shares | — | -$1.20 | -$0.48 | -$4.15 | -$4.44 | -$7.56 | -$10.92 | — | — | — | — | — | — | — | — |
| shares | — | 11.18M | 8.5M | 7.28M | 7.05M | 5.1M | 2.51M | 1.3M | 894.37K | 269.36K | 69.58K | 2.12M | 1.21M | 57.03K | 50.78K |
| shares | — | 11.18M | 8.5M | 7.28M | 7.05M | 5.1M | 2.51M | 1.3M | 894.37K | 269.36K | 69.58K | 2.12M | 1.21M | 57.03K | 50.78K |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.40×
EV/EBIT
—
Biotechnology median 26.60×
P/E (TTM)
—
Biotechnology median 7.02×
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Reportable Segment | $1,030,193 | $9,784 | $2,807,885 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2020 |
|---|---|---|---|---|---|
| License And Collaboration Revenues | $12,000,000 | — | — | — | — |
| License | $1,030,193 | $9,784 | $1,000,000 | $10,000,000 | — |
| Milestone Revenue | — | — | $1,800,000 | $0 | — |
| Royalty Revenue | — | — | — | — | $26,000 |
| Royalty | — | — | $7,885 | $0 | — |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Reportable Segment | -$13,552,334 | -$23,451,485 | -$30,939,880 |
Operating Margin by Segment (%)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Reportable Segment | -1315.5% | -239692.2% | -1101.9% |